Key clinical point: In transplant-ineligible patients with untreated mantle cell lymphoma (MCL), bendamustine, rituximab, ibrutinib, and rituximab maintenance (BR-Ibrutinib+R) and bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) should be the preferred immunotherapy regimens for improving progression-free survival (PFS) and overall survival (OS), respectively.
Major finding: BR-Ibrutinib+R resulted in the best PFS, with a surface under the cumulative ranking curve (SUCRA) of 0.89 and probability of being the best treatment (PbBT) of 69% followed by bendamustine, rituximab, and rituximab maintenance (SUCRA 0.76; PbBT 11%). VR-CAP provided the best OS, with a SUCRA of 0.89 and PbBT of 63% followed by bendamustine and rituximab regimen (SUCRA 0.74; PbBT 22%).
Study details: The data come from a network meta-analysis of nine randomized controlled trials involving 2897 transplant-ineligible patients who received first-line chemoimmunotherapy for MCL.
Disclosures: This study was funded by the Achievement Transformation Project and others. The authors declared no conflicts of interest.
Source: Jing C et al. Efficacy of front-line immunochemotherapy for transplant-ineligible mantle cell lymphoma: A network meta-analysis of randomized controlled trials. Cancer Med. 2023 (Jun 1). doi: 10.1002/cam4.6183